Postes actifs de Bruce Seligmann
Sociétés | Poste | Début | Fin |
---|---|---|---|
BioSypder Technologies, Inc.
BioSypder Technologies, Inc. Medical SpecialtiesHealth Technology BioSpyder Technologies, Inc. is a biotechnology company based in Carlsbad, CA. BioSpyder Technologies has developed a novel product for targeted sequencing called Tempo-Seq, which is a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. Tempo-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. The assay content is flexible and customizable, delivering unprecedented accuracy and sensitivity with simplified data analysis that eliminates the need for bioinformatics. Tempo-Seq assays deliver an easy-to-use solution for customers doing expression profiling for any species. The private company was founded in 2011 by Joel McComb, Bruce Seligmann, and Joanne Yeakley, with Joel McComb serving as the CEO since then. | Directeur Technique/Scientifique/R&D | 01/12/2012 | - |
Fondateur | 01/12/2012 | - |
Historique de carrière de Bruce Seligmann
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
BioSypder Technologies, Inc.
BioSypder Technologies, Inc. Medical SpecialtiesHealth Technology BioSpyder Technologies, Inc. is a biotechnology company based in Carlsbad, CA. BioSpyder Technologies has developed a novel product for targeted sequencing called Tempo-Seq, which is a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. Tempo-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. The assay content is flexible and customizable, delivering unprecedented accuracy and sensitivity with simplified data analysis that eliminates the need for bioinformatics. Tempo-Seq assays deliver an easy-to-use solution for customers doing expression profiling for any species. The private company was founded in 2011 by Joel McComb, Bruce Seligmann, and Joanne Yeakley, with Joel McComb serving as the CEO since then. | Health Technology |
- Bourse
- Insiders
- Bruce Seligmann
- Expérience